The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
golimumab · Solution
3 marketed package NDCs · 2 active manufacturers
Most dispensed: 50 mg/.5mL · Injection, Solution · #1 syringe/carton / .5 ml in 1 syringe · 100 mg/mL · Injection, Solution · #1 syringe/carton / 1 ml in 1 syringe · 50 mg/.5mL · Injection, Solution · #1 syringe, glass/carton / .5 ml in 1 syringe, glass
What changed in the last 90 days
Every detected change for golimumab, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- SimponiJul 22, 2026Price downNADAC $12970.10286 → $12909.942 per unit (-0.46%)
Same drug class
Other molecules FDA puts in Tumor Necrosis Factor Blocker, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Golimumab in shortage right now?
- No. FDA does not currently list Golimumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Golimumab?
- 2 companies have marketed Golimumab in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
- What does Golimumab cost?
- The typical pharmacy pays about $12,909.94 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.